Skip to main content

Advertisement

Table 1 Age-standardized mortality and incidence rates, by cancer site, 1993–2013

From: The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013

Cancer site Both sexes Female Male
Mortality Incidence Mortality Incidence Mortality Incidence
1993 2003 2013 2002 2012 1993 2003 2013 2002 2012 1993 2003 2013 2002 2012
C00–97, B21 all cancers 73.7 73.0 62.3 147.3 131.9 72.4 69.0 59.9 150.0 139.9 75.0 77.0 64.7 144.5 123.9
C00–14 lip, oral cavity and pharynx 1.2 1.1 1.0 3.4 3.2 0.7 0.7 0.6 2.2 2.2 1.6 1.5 1.3 4.5 4.1
C15 oesophagus 1.2 1.2 0.9 1.5 1.1 0.6 0.5 0.4 0.8 0.5 1.8 1.8 1.4 2.2 1.6
C16 stomach 7.7 6.4 4.7 11.3 7.0 6.4 5.3 4.0 9.4 6.0 9.0 7.4 5.3 13.1 7.9
C18–21 colon, rectum and anus 3.0 3.6 4.4 7.5 7.8 2.9 3.4 3.8 7.0 6.7 3.0 3.8 4.9 7.9 8.9
C25 pancreas   3.7 3.3 4.7 3.9   3.6 3.3 4.7 3.8   3.8 3.3 4.6 3.9
C33–34 lung (incl. trachea and bronchus) 10.3 8.8 5.7 11.9 7.7 5.2 4.9 3.8 6.7 4.9 15.4 12.7 7.6 17.0 10.5
C43 melanoma of skin 0.4 0.5 0.5 1.6 1.8 0.3 0.3 0.4 1.7 1.5 0.4 0.6 0.5 1.4 2.1
C50 breast 4.3 4.5 4.5 13.2 17.7 8.6 9.0 9.0 26.4 35.4      
C53 cervix uteri 6.9 5.0 3.1 14.8 11.7 13.7 9.9 6.1 29.5 23.3      
C56 ovary   1.7 1.7 3.7 2.8   3.3 3.4 7.4 5.6      
C61 prostate 4.9 6.1 5.0 15.0 13.7       9.8 12.1 10.0 29.9 27.3
C64 kidney   1.9 1.8 4.7 3.6   1.3 1.3 4.0 2.5   2.5 2.3 5.4 4.6
C70–72 brain, central nervous system   2.0 1.8 3.0 4.0   1.6 1.5 2.4 3.3   2.3 2.1 3.5 4.6
C73 thyroid   0.6 0.6 3.4 2.6   0.7 0.7 5.7 3.9   0.4 0.4 1.0 1.3
C81 hodgkin lymphoma   0.5 0.4 1.7 1.3   0.4 0.3 1.2 1.1   0.6 0.5 2.1 1.5
C82–85, C96 non-Hodgkin lymphoma   2.1 2.0 4.8 4.1   1.8 1.6 3.9 3.6   2.3 2.3 5.7 4.6
C88 + C90 multiple myeloma   1.0 1.0 1.4 1.3   0.8 0.9 1.2 1.1   1.1 1.1 1.6 1.4
C91–95 leukemia 3.2 3.7 3.3 5.0 5.6 2.9 3.3 3.0 4.3 5.1 3.4 4.1 3.6 5.6 6.0